Mylan Settles Over Bilking Medicaid, But No Word on 340B Refunds
by Admin | October 11, 2016 2:09 pm
October 11, 2016—Embattled EpiPen manufacturer Mylan has agreed to a $465 million settlement with the U.S. Justice Department to resolve claims the company underpaid Medicaid drug rebates[1] by misclassifying EpiPen as a generic rather than brand-name product. It is unclear if the deal will compensate healthcare providers in the 340B drug discount program[2] for Mylan overcharges.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[3].
Already registered? Click here to login[4]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)
Endnotes:- underpaid Medicaid drug rebates: http://340binformed.org/2016/10/youre-busted-mylan-bilks-medicaid-feds-confirm/
- 340B drug discount program: https://www.youtube.com/watch?v=_OnL4ueIPXU
- Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
- Click here to login: http://340binformed.org/reader-login/
Source URL: https://340binformed.org/2016/10/mylan-settles-over-bilking-medicaid-but-no-word-on-340b-refunds/